Meridian Bioscience Past Earnings Performance
Past criteria checks 1/6
Meridian Bioscience has been growing earnings at an average annual rate of 25.3%, while the Medical Equipment industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 13% per year. Meridian Bioscience's return on equity is 11.5%, and it has net margins of 12.7%.
Key information
25.3%
Earnings growth rate
24.7%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 13.0% |
| Return on equity | 11.5% |
| Net Margin | 12.7% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M
Aug 05Meridian Bioscience: High-Probability Merger Arbitrage
Jul 26Meridian Bioscience downgraded at William Blair on $1.53B acquisition
Jul 07Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet
Jun 27
Meridian Bioscience: Correctly Valued
Jun 26Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital
Jun 09Meridian Bioscience: Deceptively Priced
Mar 14Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns
Feb 03These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely
Jul 19If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy
Jul 08Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine
May 10Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation
May 08Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly
Mar 31Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?
Mar 11Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%
Feb 24Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues
Feb 09
Meridian expands production capacity for COVID-19 tests with NIH funding
Feb 03Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?
Jan 27Revenue & Expenses Breakdown
How Meridian Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 333 | 42 | 88 | 24 |
| 30 Jun 22 | 344 | 43 | 90 | 24 |
| 31 Mar 22 | 339 | 62 | 86 | 24 |
| 31 Dec 21 | 313 | 60 | 80 | 24 |
| 30 Sep 21 | 318 | 71 | 76 | 24 |
| 30 Jun 21 | 306 | 71 | 76 | 25 |
| 31 Mar 21 | 327 | 87 | 76 | 25 |
| 31 Dec 20 | 299 | 70 | 74 | 25 |
| 30 Sep 20 | 254 | 46 | 71 | 24 |
| 30 Jun 20 | 240 | 44 | 68 | 22 |
| 31 Mar 20 | 204 | 21 | 64 | 20 |
| 31 Dec 19 | 197 | 19 | 61 | 19 |
| 30 Sep 19 | 201 | 24 | 62 | 18 |
| 30 Jun 19 | 203 | 26 | 62 | 16 |
| 31 Mar 19 | 207 | 27 | 64 | 16 |
| 31 Dec 18 | 213 | 26 | 68 | 16 |
| 30 Sep 18 | 214 | 24 | 70 | 17 |
| 30 Jun 18 | 210 | 24 | 69 | 18 |
| 31 Mar 18 | 209 | 18 | 68 | 17 |
| 31 Dec 17 | 206 | 22 | 66 | 17 |
| 30 Sep 17 | 201 | 22 | 63 | 16 |
| 30 Jun 17 | 198 | 21 | 63 | 15 |
| 31 Mar 17 | 199 | 30 | 63 | 15 |
| 31 Dec 16 | 195 | 30 | 61 | 14 |
| 30 Sep 16 | 196 | 32 | 59 | 14 |
| 30 Jun 16 | 195 | 35 | 58 | 13 |
| 31 Mar 16 | 192 | 36 | 55 | 13 |
Quality Earnings: VIVO has a large one-off loss of $21.2M impacting its last 12 months of financial results to 30th September, 2022.
Growing Profit Margin: VIVO's current net profit margins (12.7%) are lower than last year (22.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VIVO's earnings have grown significantly by 25.3% per year over the past 5 years.
Accelerating Growth: VIVO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: VIVO had negative earnings growth (-40.5%) over the past year, making it difficult to compare to the Medical Equipment industry average (3.7%).
Return on Equity
High ROE: VIVO's Return on Equity (11.5%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/02/01 08:26 |
| End of Day Share Price | 2023/01/30 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2022/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Meridian Bioscience, Inc. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Mark Massaro | Canaccord Genuity |
| Zarak Khurshid | Caris & Company |